Frexalimab is being investigated for the treatment of multiple sclerosis, systemic lupus erythematosus, Sjögren's syndrome, and type 1 diabetes; it may help prevent the destruction of β-cells by inhibiting the interaction between CD40 and CD40 ligand (CD40L), thereby modulating immune responses.